Adaptive Biotechnologies Corporation (ADPT)
ADPT Stock Price Chart
Explore Adaptive Biotechnologies Corporation interactive price chart. Choose custom timeframes to analyze ADPT price movements and trends.
ADPT Company Profile
Discover essential business fundamentals and corporate details for Adaptive Biotechnologies Corporation (ADPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jun 2019
Employees
624.00
Website
https://www.adaptivebiotech.comCEO
Chad Robins
Description
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
ADPT Financial Timeline
Browse a chronological timeline of Adaptive Biotechnologies Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.13, while revenue estimate is $65.44m.
Earnings released on 5 May 2026
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $70.90m , beating expectations by +16.16%.
Earnings released on 5 Feb 2026
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $71.68m , beating expectations by +17.72%.
Earnings released on 6 Nov 2025
EPS came in at $0.06 surpassing the estimated -$0.18 by +133.33%, while revenue for the quarter reached $93.97m , beating expectations by +45.40%.
Earnings released on 5 Aug 2025
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $58.88m , beating expectations by +19.20%.
Earnings released on 5 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.34 by +41.18%, while revenue for the quarter reached $52.44m , beating expectations by +22.88%.
Earnings released on 12 Feb 2025
EPS came in at -$0.23 surpassing the estimated -$0.27 by +14.81%, while revenue for the quarter reached $47.46m , beating expectations by +3.06%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.29 by +24.14%, while revenue for the quarter reached $46.44m , beating expectations by +15.41%.
Earnings released on 1 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$0.33 by +6.06%, while revenue for the quarter reached $43.19m , beating expectations by +11.80%.
Earnings released on 7 May 2024
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%, while revenue for the quarter reached $41.87m , beating expectations by +7.98%.
Earnings released on 13 Feb 2024
EPS came in at -$0.48 falling short of the estimated -$0.33 by -45.45%, while revenue for the quarter reached $45.78m , missing expectations by -5.51%.
Earnings released on 9 Nov 2023
EPS came in at -$0.48 falling short of the estimated -$0.33 by -45.45%, while revenue for the quarter reached $37.92m , missing expectations by -11.74%.
Earnings released on 2 Aug 2023
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $48.93m , beating expectations by +9.03%.
Earnings released on 3 May 2023
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.26%, while revenue for the quarter reached $37.65m , beating expectations by +2.27%.
Earnings released on 14 Feb 2023
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $55.20m , beating expectations by +0.87%.
Earnings released on 3 Nov 2022
EPS came in at -$0.32 surpassing the estimated -$0.38 by +15.79%, while revenue for the quarter reached $47.83m , beating expectations by +0.04%.
Earnings released on 3 Aug 2022
EPS came in at -$0.37 surpassing the estimated -$0.43 by +13.95%, while revenue for the quarter reached $43.66m , beating expectations by +4.43%.
Earnings released on 4 May 2022
EPS came in at -$0.44 surpassing the estimated -$0.46 by +4.35%, while revenue for the quarter reached $38.62m , beating expectations by +2.24%.
Earnings released on 15 Feb 2022
EPS came in at -$0.43 surpassing the estimated -$0.45 by +4.44%, while revenue for the quarter reached $37.93m , beating expectations by +4.30%.
Earnings released on 3 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $39.47m , beating expectations by +6.47%.
Earnings released on 4 Aug 2021
EPS came in at -$0.35 surpassing the estimated -$0.43 by +18.60%, while revenue for the quarter reached $38.51m , beating expectations by +23.18%.
ADPT Stock Performance
Access detailed ADPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
